Literature DB >> 17938376

Effect of endothelin 1 genotype on blood pressure is dependent on physical activity or fitness levels.

Tuomo Rankinen1, Timothy Church, Treva Rice, Nathan Markward, Arthur S Leon, Dabeeru C Rao, James S Skinner, Steven N Blair, Claude Bouchard.   

Abstract

Contributions of the DNA sequence variation at the endothelin 1 locus to the risk of hypertension and to endurance training-induced changes in blood pressure were investigated in the Aerobics Center Longitudinal Study and the Health, Risk Factors, Exercise Training and Genetics Family Study cohorts. We identified 586 normotensive control subjects and 607 incident hypertensive case subjects from the Aerobics Center Longitudinal Study cohort (all whites) who were normotensive and healthy at their first clinic visit. The case subjects were diagnosed with hypertension during an average follow-up of 9.5 years, whereas the control subjects remained normotensive. The allele and genotype frequencies of 5 endothelin 1 haplotype tagging single nucleotide polymorphisms did not differ significantly between the case and control subjects. However, we observed a significant (P=0.0025) interaction between the endothelin 1 rs5370 (G/T; Lys198Asn) genotype and cardiorespiratory fitness level on the risk of hypertension: among low-fit subjects, the rs5370 minor allele (T; 198Asn) was associated with higher risk of hypertension (odds ratio: 1.95; 95% CI: 1.36 to 2.81; P=0.0003), whereas the risk did not differ among genotypes in high-fit subjects. In the white Health, Risk Factors, Exercise Training and Genetics subjects (N=480), the rs5370 T allele was associated with blunted systolic blood pressure (P=0.0046) and pulse pressure (P=0.0016) responses to a 20-week endurance training program. The Lys198Asn variant of the endothelin 1 locus is associated with blood pressure phenotypes in whites. However, the expression of the genotype effect is modulated by physical activity or cardiorespiratory fitness level. Our study provides an illustrative example of how physical activity and fitness level modifies the associations between a candidate gene and outcome phenotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938376     DOI: 10.1161/HYPERTENSIONAHA.107.093609

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  23 in total

1.  Genetic effects of adiponectin single nucleotide polymorphisms on the clustering of metabolic risk factors in young Korean adults.

Authors:  Ji-Young Lee; Jin-Kyung Cho; Hye-Ryun Hong; Young-Yoon Jin; Hyun-Sik Kang
Journal:  Eur J Appl Physiol       Date:  2011-06-01       Impact factor: 3.078

2.  Interactions of genetic variants with physical activity are associated with blood pressure in Chinese: the GenSalt study.

Authors:  May E Montasser; Donfeng Gu; Jing Chen; Lawrence C Shimmin; Charles Gu; Tanika N Kelly; Cashell E Jaquish; Treva Rice; Dabeeru C Rao; Jie Cao; Jichun Chen; De-Pei Liu; Paul K Whelton; Jiang He; James E Hixson
Journal:  Am J Hypertens       Date:  2011-06-09       Impact factor: 2.689

3.  Dysregulated aldosterone secretion in persons of African descent with endothelin-1 gene variants.

Authors:  Jia W Tan; Tina Gupta; Worapaka Manosroi; Tham M Yao; Paul N Hopkins; Jonathan S Williams; Gail K Adler; Jose R Romero; Gordon H Williams
Journal:  JCI Insight       Date:  2017-12-07

4.  Positional identification of variants of Adamts16 linked to inherited hypertension.

Authors:  Bina Joe; Yasser Saad; Seema Dhindaw; Norman H Lee; Bryan C Frank; Ovokeraye H Achinike; Truong V Luu; Kathirvel Gopalakrishnan; Edward J Toland; Phyllis Farms; Shane Yerga-Woolwine; Ezhilarasi Manickavasagam; John P Rapp; Michael R Garrett; David Coe; Suneel S Apte; Tuomo Rankinen; Louis Pérusse; Georg B Ehret; Santhi K Ganesh; Richard S Cooper; Ashley O'Connor; Treva Rice; Alan B Weder; Aravinda Chakravarti; Dabeeru C Rao; Claude Bouchard
Journal:  Hum Mol Genet       Date:  2009-05-07       Impact factor: 6.150

5.  Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.

Authors:  S P Gampenrieder; C Hufnagl; S Brechelmacher; F Huemer; H Hackl; G Rinnerthaler; F Romeder; C Monzo Fuentes; P Morre; C Hauser-Kronberger; B Mlineritsch; R Greil
Journal:  Pharmacogenomics J       Date:  2016-05-03       Impact factor: 3.550

6.  Modification effects of physical activity and protein intake on heritability of body size and composition.

Authors:  Karri Silventoinen; Ann Louise Hasselbalch; Tea Lallukka; Leonie Bogl; Kirsi H Pietiläinen; Berit L Heitmann; Karoline Schousboe; Aila Rissanen; Kirsten O Kyvik; Thorkild I A Sørensen; Jaakko Kaprio
Journal:  Am J Clin Nutr       Date:  2009-08-26       Impact factor: 7.045

7.  The effects of ethnic discrimination and socioeconomic status on endothelin-1 among blacks and whites.

Authors:  Denise C Cooper; Paul J Mills; Wayne A Bardwell; Michael G Ziegler; Joel E Dimsdale
Journal:  Am J Hypertens       Date:  2009-04-23       Impact factor: 2.689

8.  Genetic test for the personalization of sport training.

Authors:  Zakira Naureen; Marco Perrone; Stefano Paolacci; Paolo Enrico Maltese; Kristjana Dhuli; Danjela Kurti; Astrit Dautaj; Roberta Miotto; Arianna Casadei; Bernard Fioretti; Tommaso Beccari; Francesco Romeo; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09

9.  Genetic variants associated with exercise performance in both moderately trained and highly trained individuals.

Authors:  N R Harvey; S Voisin; P J Dunn; H Sutherland; X Yan; M Jacques; I D Papadimitriou; L J Haseler; K J Ashton; L M Haupt; N Eynon; L R Griffiths
Journal:  Mol Genet Genomics       Date:  2020-01-02       Impact factor: 3.291

10.  Differential Impact of Stress Reduction Programs upon Ambulatory Blood Pressure among African American Adolescents: Influences of Endothelin-1 Gene and Chronic Stress Exposure.

Authors:  Mathew J Gregoski; Vernon A Barnes; Martha S Tingen; Yanbin Dong; Haidong Zhu; Frank A Treiber
Journal:  Int J Hypertens       Date:  2011-11-24       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.